PMID- 12744891
OWN - NLM
STAT- MEDLINE
DCOM- 20040105
LR  - 20190728
IS  - 0264-410X (Print)
IS  - 0264-410X (Linking)
VI  - 21
IP  - 19-20
DP  - 2003 Jun 2
TI  - Safety and protective efficacy of porcine reproductive and respiratory syndrome 
      recombinant virus vaccines in young pigs.
PG  - 2556-63
AB  - Three porcine reproductive and respiratory syndrome virus (PRRSV) recombinants, 
      generated by mutagenesis of an infectious cDNA clone of the Lelystad virus (LV) 
      isolate, were tested for their safety and protective efficacy as potential PRRSV 
      vaccines in pigs. Recombinant vABV688 contains two amino acid substitutions in 
      the minor structural protein GP(2) resulting in improved growth on cell line 
      CL2621; in recombinant vABV707 the region encoding the ectodomain of the major 
      unglycosylated membrane protein M has been replaced by that of the murine lactate 
      dehydrogenase-elevating arterivirus; recombinant vABV746 lacks the six C-terminal 
      amino acids of the nucleocapsid protein N. First, we determined the safety of 
      these recombinant viruses by monitoring the stability of the introduced mutations 
      in 8-week-old pigs. We showed that the introduced genomic mutations were 
      maintained throughout the viraemic period. Second, the protective efficacy of 
      immunization with the recombinant viruses against challenge with a homologous and 
      a heterologous PRRSV strain was determined in two pigs and compared with the 
      efficacy of vABV437, a virus derived from the parental LV cDNA. The viraemia in 
      pigs immunized with the recombinant viruses was reduced compared to pigs 
      immunized with vABV437. In addition, the length of viraemia was reduced in the 
      sentinel pigs that were introduced into the groups immunized with vABV746, 
      vABV688, and vABV707, however, all of the sentinel pigs became infected. Pigs 
      immunized with vABV707 and vABV437 were protected against challenge with 
      homologous virus LV-Ter Huurne and transmission of the latter virus. None of the 
      immunized pigs were protected against heterologous challenge with the virulent US 
      isolate SDSU#73, but the vABV707- and vABV746-immunized pigs were protected 
      against transmission of this virus from challenged pigs. In conclusion, the 
      obtained viral recombinants are interesting candidates to be further explored for 
      their use as vaccines against PRRSV.
FAU - Verheije, M H
AU  - Verheije MH
AD  - Department of Infectious Diseases and Food Chain Quality, Institute for Animal 
      Science and Health, Lelystad, The Netherlands. h.verheije@vet.uu.nl
FAU - Kroese, M V
AU  - Kroese MV
FAU - van der Linden, I F A
AU  - van der Linden IF
FAU - de Boer-Luijtze, E A
AU  - de Boer-Luijtze EA
FAU - van Rijn, P A
AU  - van Rijn PA
FAU - Pol, J M A
AU  - Pol JM
FAU - Meulenberg, J J M
AU  - Meulenberg JJ
FAU - Steverink, P J G M
AU  - Steverink PJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (DNA Primers)
RN  - 0 (Vaccines, Synthetic)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Amino Acid Substitution
MH  - Animals
MH  - Base Sequence
MH  - Cells, Cultured
MH  - DNA Primers
MH  - Macrophages, Alveolar/cytology/virology
MH  - Porcine Reproductive and Respiratory Syndrome/*immunology/*prevention & control
MH  - Porcine respiratory and reproductive syndrome virus/*immunology
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Safety
MH  - Swine
MH  - Time Factors
MH  - Vaccines, Synthetic/*therapeutic use
MH  - Viral Vaccines/*therapeutic use
EDAT- 2003/05/15 05:00
MHDA- 2004/01/06 05:00
CRDT- 2003/05/15 05:00
PHST- 2003/05/15 05:00 [pubmed]
PHST- 2004/01/06 05:00 [medline]
PHST- 2003/05/15 05:00 [entrez]
AID - S0264410X03000471 [pii]
AID - 10.1016/s0264-410x(03)00047-1 [doi]
PST - ppublish
SO  - Vaccine. 2003 Jun 2;21(19-20):2556-63. doi: 10.1016/s0264-410x(03)00047-1.